In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and the COPD Foundation. This collaboration aims to enhance healthcare access by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for COPD patients in the US. […]
Lupin has announced that its subsidiary in Canada, Lupin Pharma Canada has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD) in Canada. Tiotropium Bromide Inhalation Powder is used as a long-term maintenance bronchodilator for patients with COPD, including […]
Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic version of Spiriva (Tiotropium bromide). Lutio has been approved for the treatment of chronic obstructive pulmonary disease (COPD). It is the second inhalation product for the British market from Lupin […]